New Bill Might Boost Recruitment Rates for Rare Disease Clinical Trials

This article in outsourcing-pharma.com discusses how a bill introduced by US Congress Representative Edward Markey would allow patients with rare diseases to disregard up to $2,000 of compensation received for participating in clinical trials. Current legislation categorizes compensation from clinical trials as income and puts patients' earnings above the Social Security Income eligibility threshold. This in turn would most likely boost recruitment rates for clinical trials for rare diseases, which has often been problematic in the past. Do you agree with the bill?